Trial Condition(s):

Multiple Sclerosis

BAY86-5046 (Betaseron), Non Interventional Studies (BETAEVAL)

Bayer Identifier:

17101

ClinicalTrials.gov Identifier:

NCT02121444

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study aims to investigate adherence to therapy among patients treated with Betaferon who are using the BETACONNECT autoinjector.

Inclusion Criteria
- Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.
- Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician.
- Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device
- Written informed consent must be obtained.
Exclusion Criteria
- Patients receiving any other disease modifying drug.
- Contraindications of Betaferon described in the Summary of Product Characteristics.

Trial Summary

Enrollment Goal
151
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design